Search Within

Devika Gajria

Formats
  1. Meeting Abstract (19)
  2. Journal Article (12)
  3. Research Letter (1)
Groups
  1. Breast Medicine Service (32)
  2. Department of Medicine (32)
  3. Solid Tumor Oncology Division (32)
  4. Survivorship Research (27)
  5. Epidemiology and Biostatistics (22)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (21)

More Groups

People
  1. Clifford Hudis (16)
  2. Shanu Modi (15)
  3. Diana Lake (13)
  4. Shari Goldfarb (13)
  5. Sujata Patil (13)
  6. Larry Norton (12)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (1)
  4. 2022 (2)
  5. 2019 (2)
  6. 2018 (2)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. Cancer Research (8)
  3. JAMA Dermatology (3)
  4. Blood (2)
  5. Breast Cancer Research and Treatment (2)
  6. Clinical Breast Cancer (2)

More Publications

Publishers
  1. American Association for Cancer Research (9)
  2. American Society of Clinical Oncology (9)
  3. American Medical Association (3)
  4. Elsevier Inc. (3)
  5. American Society of Hematology (2)
  6. Springer (2)

More Publishers

Results (32)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Use of dupilumab to manage antibody-drug conjugate-induced cutaneous toxicities
    Research Letter

    Nykaza, I.; Dusza, S. W.; Rosenberg, J. E.; Iyer, G.; Feld, E.; Chandarlapaty, S.; Jhaveri, K.; Lacuna, K.; Gajria, D.; Bielawa, M.; more...
    JAMA Dermatology (2025)

    Fulltext@MSK | Save
  • Oral minoxidil for late alopecia in cancer survivors
    Journal Article

    Kuo, A. M. S.; Reingold, R. E.; Ketosugbo, K. F.; Pan, A.; Kraehenbuehl, L.; Dusza, S.; Gajria, D.; Lake, D. E.; Bromberg, J. F.; Traina, T. A.; more...
    Breast Cancer Research and Treatment (2024)

    Fulltext@MSK | Save
  • Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: A randomized trial
    Journal Article

    Scott, J. M.; Lee, J.; Herndon, J. E.; Michalski, M. G.; Lee, C. P.; O'Brien, K. A.; Sasso, J. P.; Yu, A. F.; Rowed, K. A.; Bromberg, J. F.; more...
    European Heart Journal (2023)

    Fulltext@MSK | Save
  • Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor-positive breast cancer
    Meeting Abstract

    Lacouture, M. E.; Pan, A.; Dranitsaris, G.; Harris, U.; Chandarlapaty, S.; Dang, C. T.; Gajria, D.; Gordon, A.; Iyengar, N. M.; Robson, M. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Oral minoxidil for the treatment of late alopecia in cancer survivors
    Meeting Abstract

    Kuo, A. M. S.; Reingold, R. E.; Ketosugbo, K.; Pan, A.; Dusza, S. W.; Kraehenbuehl, L.; Gajria, D.; Lake, D. E.; Bromberg, J.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • CDK4/6 plus aromatase inhibitor-induced alopecia in breast cancer patients
    Meeting Abstract

    Chan, D.; Freites Martinez, A. D.; Goldfarb, S. B.; Modi, S.; Gajria, D.; Lacouture, M. E.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia
    Journal Article

    Freites-Martinez, A.; Chan, D.; Sibaud, V.; Shapiro, J.; Fabbrocini, G.; Tosti, A.; Cho, J.; Goldfarb, S.; Modi, S.; Gajria, D.; more...
    JAMA Dermatology (2019)

    Fulltext@MSK | Save
  • Co-targeting ER and FGFR in patients with ER+/HER2- FGFR amplified (amp) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Syed, U.; Wong, S.; D'Andrea, G.; Lake, D.; Goldfarb, S.; Gajria, D.; Ligresti, L.; Rogado, A.; Reis-Filho, J.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Endocrine therapy-induced alopecia in patients with breast cancer
    Journal Article

    Freites-Martinez, A.; Shapiro, J.; Chan, D.; Fornier, M.; Modi, S.; Gajria, D.; Dusza, S.; Goldfarb, S.; Lacouture, M. E.
    JAMA Dermatology (2018)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save